Meet DGD Pharma’s Management Team

team

Vlad Vitoc, MD, MBA

Chief Executive Officer
Dr. Vitoc is a biotech executive with a broad array of experience across commercial strategic analysis and planning and medical affairs, in which he has 20 years of experience. He has served on leadership teams in several Oncology companies and business units. He also has a track record of successful organizational capability building, talent recruiting and development, and functional leadership.
team

Angela Wang, CPA EMBA

Chief Finance Officer
Angela is the Chief Finance Officer with over 25 years of global financial and commercial leadership experience in the pharmaceutical/biotech industry. She has worked in Europe, Asia and N. American, built and led cross-functional teams with solid results.

She started her career with one of the Big 6 accounting firms and worked alongside China’s Ministry of Finance in developing China’s first set of accounting standards. Following her appointment in public accounting, she joined the pharma industry in financial and commercial leadership roles in increasing levels of responsibilities over the years. First as Country CFO in China for Novartis, Angela led the funding and financial responsibilities for 10 subsidiaries and set up the first corporate finance function. Subsequently, she become Group Controller in the Novartis head office in Switzerland, working alongside the Group CEO and CFO, responsible for the global Pharma division covering planning, analysis, and review of all major investments, divestments and mergers and acquisitions. 

With growing investments in China, Angela returned to build and lead the China Pharma strategy and business development function.  Aligned with the long-term plan, Angela led the team to identify, negotiate and implement in-license and out-license partnerships in the areas of dermatology, liver disease, and incontinence.  Meanwhile, as China is a high prevalence country for hepatitis, she led a cross-functional team comprising local and global counterparts in clinical, regulatory, pricing, manufacturing and marketing towards expediting approval of the local hepatitis B treatment Sebivo. Subsequently, Angela was the Business Unit Head for Ophthalmology, responsible for sales and marketing where she turned around a historically underperforming business and led the team to exceed sales targets with double digit growth. With strong customer relations, the team also won support from key opinion leaders to initiate a fast-track approval request for Lucentis.

Following Novartis, Angela was CFO for Syngenta, supporting its China Agrichemical business responsible for planning, accounting, internal controls, pricing, and compliance. She was also the CFO for Sanofi China supporting over $1 billion in sales, covering Finance, Legal, Supply Chain and Site Management. 

Beyond corporations, Angela also works closely with startups as an entrepreneurial advisor to support their early stage growth, business development and scale up.  As a senior advisor to a global non-profit think tank, she has published with focus on innovation, research and development. Angela has worked in Europe, Asia and North America, and speaks Mandarin, German and French.

Angela is a Certified Public Accountant and holds an Executive Master of Business Administration from the International Institute for Management Development (IMD) in Lausanne, Switzerland, and a Bachelor of Science in Financial Accounting from Rutgers University in New Brunswick, New Jersey.

Read More
team

Daniel Relovsky

Chief Operating Officer
Dan Relovsky is the Chief Operating Officer for Maia Biotechnology, Inc. He is a general management, operations and commercialization specialist that has served in the pharmaceutical and biotechnology industries for over 25 years.

Mr. Relovsky was the founding and managing partner for Clarity Global Solutions LLC, a consulting firm specializing in commercial value development and operational support to biotech and pharmaceutical companies, with primary focus on early-mid stage asset development and product planning building commercial value.  Additionally, CGS specializes in therapeutic area market development and engagement, Medical Affairs and Commercial Operations management, with particular focus on commercialization and launch preparation. 

Mr. Relovsky began his career in Finance for Squibb-Novo, Inc. (now Novo Nordisk Pharmaceuticals, Inc.) and over the years has held various management positions, with increasing levels of responsibility, including leading operations functional areas, Product Planning and Marketing, addressing both company-wide and product level initiatives.  Most recently, Mr. Relovsky has established and led the Commercial Operations and launch planning for ARS Pharmaceuticals, Inc. for an intranasal form of epinephrine (ARS-1).  Prior to ARS, he led Medical Affairs Operations for Puma Biotechnology, Inc. through the launch of NERLYNX (neratinib), a tyrosine kinase inhibitor approved for the treatment of breast cancer.  He has also held positions leading Commercial Operations for Somaxon Pharmaceuticals, Inc. which launched SILENOR (doxepin) for the treatment of insomnia; and Marketing for Cephalon, Inc. where he established the oncology franchise that included the product re-launch of TRISENOX (arsenic trioxide) in acute promyelocytic leukemia (APL) and launch of TREANDA (bendamustine) in two indications: chronic lymphocytic leukemia (CLL) and indolent non-hodgkin lymphoma (NHL).  Other previous positions include product planning and marketing with Salmedix, Inc., Maxim Pharmaceuticals, Inc.; and commercial operations with Agouron Pharmaceutics, Inc. all based in San Diego, CA; and IMS Health (now IQVIA). Additionally, Mr. Relovsky held the role of Vice President, Development & Board Member for the American Melanoma Foundation. 

Mr. Relovsky holds a Bachelor of Science, Business Administration and Finance from Drexel University in Philadelphia, PA.

Read More
team

Wayne Klohs, PhD

Head of Drug Development
Dr. Klohs has over thirty-five years of experience in the pharmaceutical industry with increasing levels of responsibility held in positions across the drug development and discovery spectrum. He currently consults for numerous biotech and pharma companies focused in oncology after retiring from Astellas Pharma Inc. as a Senior Vice President and Global Therapeutic Head for Oncology.